Elevated serum levels (above cut-off values) of CEA, CA125 and CA15-3 were identified in 13 (8.6%), 21 (13.9%) and 14 (9.3%) breast cancer cases, but not observed in breast benign diseases. This evidence concerns the gene MUC16 and breast carcinoma.